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CD8+ T cell tolerance, although essential for prevent-
ing autoimmunity, poses substantial obstacles to
eliciting immune responses to tumor antigens, which
are generally overexpressed normal proteins. Devel-
opment of effective strategies to overcome tolerance
for clinical applications would benefit from elucida-
tion of the immunologic mechanism(s) regulating T
cell tolerance to self. To examine how tolerance is
maintained in vivo, we engineered dual-T cell recep-
tor (TCR) transgenic mice in which CD8+ T cells rec-
ognize two distinct antigens: a foreign viral-protein
and a tolerizing self-tumor protein. Encounter with
peripheral self-antigen rendered dual-TCR T cells
tolerant to self, but these cells responded normally
through the virus-specific TCR. Moreover, prolifera-
tion induced by virus rescued function of tolerized
self-tumor-reactive TCR, restoring anti-tumor activ-
ity. These studies demonstrate that peripheral CD8+
T cell tolerance to self-proteins can be regulated
at the level of the self-reactive TCR complex rather
than by central cellular inactivation and suggest
an alternate strategy to enhance adoptive T cell
immunotherapy.
INTRODUCTION
Immune-mediated destruction of normal tissues is limited by
deletion of autoreactive lymphocytes during development.
However, some self-reactive T cells evade thymic deletion
(Danke et al., 2004; Huseby et al., 2001; Lo et al., 1988; Morahan
et al., 1989; Ohlen et al., 2002; Steinman, 2001), making periph-
eral tolerance induction essential to prevent autoimmunity. Un-
fortunately, CD8+ T cell tolerance to self-antigens can interfere
with generation of effective T cell responses to tumors because
many potentially targetable tumor-associated antigens are aber-
rantly expressed self-proteins (Pardoll, 2003). Therefore, mech-
anisms that maintain tolerance have implications for both auto-
immune disease and tumor immunology.662 Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc.In mice and humans, T cells commonly transcribe more than
the two T cell receptor (TCR) chains required for one functional
TCR, with such cells constituting nearly one-third of peripheral
T cells (Casanova et al., 1991; Padovan et al., 1993), although
the number of cells actually expressing two major histocompat-
ibility complex (MHC)-restricted TCRs (dual TCRs) on the cell
surface is predictably lower (Hardardottir et al., 1995; Nieder-
berger et al., 2003). Nevertheless, such dual-TCR T cells could
contribute to autoimmunity if a self-reactive TCR evades the thy-
mic deletion process and enters the periphery after thymic selec-
tion of a second nonself-reactive TCR (Hardardottir et al., 1995;
Heath and Miller, 1993; Padovan et al., 1993; Zal et al., 1996). Al-
though the self-reactive TCR should still receive tolerizing signals
in the periphery, it is unclear whether such dual-TCR CD8+ T cells
would become tolerant to all subsequent TCR signals or remain
responsive to signals delivered through the other TCR. Thus, the
issue is where tolerance is controlled within a tolerized T cell—
are downstream cellular pathways not activated because of de-
ficient signaling by a tolerant dysfunctional TCR complex, or is
a tolerant cell programmed to not respond to signaling from a po-
tentially competent TCR? Some insights have been provided by
analyses of in vitro responses. With CD4+ T cells expressing two
class II-restricted receptors, antagonism of one TCR by in vitro
stimulation with altered peptide ligands (APLs) inhibited prolifer-
ation to subsequent stimulation via either TCR (Dittel et al., 1999;
Robertson and Evavold, 1999; Yang and Grey, 2003), implying
central tolerizing mechanisms and supported by reduced phos-
phorylation of proximal signaling components and accumulation
of negative regulatory proteins at both TCR complexes (Dittel
et al., 1999). In contrast, trans-inhibition in CD8+ T cells express-
ing two class I-restricted receptors after stimulation with APLs
has been controversial, observed with proliferation but not effec-
tor functions as the readout (Daniels et al., 1999; Gascoigne and
Zal, 2004; Stotz et al., 1999; Yang and Grey, 2003). Because
proliferative defects are the hallmark of in vivo-tolerized CD8+
T cells, which often retain effector functions (Ohlen et al., 2002;
Tanchot et al., 1998; Teague et al., 2006), the absence of prolifer-
ation may be the more relevant observation. Thus these in vitro
systems have suggested the existence of a central mechanism
regulating tolerance within the cell, but generalizing results with
in vitro APL systems to in vivo tolerance of self-proteins may be
misleading. The only previous analysis of dual-TCR T cells toler-
ized in vivo evaluated CD4+ T cells expressing one TCR restricted
to a nonexpressed class II allele, and one class I-restricted TCR
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CD8+ T cell tolerance to self-proteins unclear (Hah et al., 2005).
How distinct TCR function in dual-TCR T cells in vivo has
implications not only for autoimmunity and the understanding
of how tolerance is mechanistically maintained in a cell with a sin-
gle TCR, but also for tumor immunotherapy (Gladow et al., 2004;
Heemskerk et al., 2004; Hughes et al., 2005; Morgan et al., 2006;
Roszkowski et al., 2005; Stanislawski et al., 2001). T cells with an
introduced second TCR are being evaluated as cellular reagents
for treatment of human cancer, but substantial obstacles still
remain (Morgan et al., 2006). By engineering a dual-TCR trans-
genic murine model, we have gained new insights into the immu-
nologic mechanisms regulating T cell tolerance and obtained ev-
idence that tolerization of the self-reactive TCR does not disrupt
signaling or function mediated via the second receptor, suggest-
ing that tolerance can be maintained proximally at the level of the
self-reactive TCR.
RESULTS
Activation of Tolerant TCR Transgenic CD8+ T Cells
We previously described a tolerance model in which TCR trans-
genic (Tg) mice (TCRGag) expressing a Db-restricted Va3Vb12
receptor specific for the immunodominant FMuLVGag epitope
were crossed with Tg mice (Alb:Gag) expressing FMuLVGag
in the liver, regulated by the albumin promoter (Ohlen et al.,
2002). Peripheral CD8+ T cells in hybrid (TCRGagxAlb:Gag) mice
exhibit attenuated TCR signaling and no proliferation in response
to stimulation with Gag-antigen (Ohlen et al., 2002). This tolerant
phenotype likely resulted from chronic encounter with antigen
presented in the liver, as suggested by analysis of mature naive
TCRGag T cells transferred into bone marrow chimeric Alb:Gag
hosts, in which the cells that persisted in the periphery had
become tolerant (Morimoto et al., 2007). To determine whether
increasing the strength of TCR signaling might overcome the
defect, naive TCRGag or tolerant TCRGagxAlb:Gag splenocytes
were stimulated with not only Gag peptide but also a potentially
stronger signal with antibodies to the TCR complex. Naive T cells
proliferated to Gag and anti-CD3 and not irrelevant Env-peptide,
but tolerant CD8+ T cells, which failed to respond to Gag as
previously reported (Ohlen et al., 2002; Teague et al., 2006), un-
expectedly proliferated in response to anti-CD3 (Figure 1A).
However, stimulation with Abs specific for the Va3Vb12 chains
of the Gag-specific TCR, which induced proliferation of naive
T cells, failed to induce tolerant T cell proliferation (Figure 1A).
These outcomes suggest that (1) the stimulus mediated by the
Tg TCR complex via ligation with anti-CD3 is sufficiently stronger
than signals generated by direct engagement of the tolerant
abTCR chains to induce a response, (2) the proliferation with
anti-CD3 reflects activation of a fraction of nontolerant CD8+
T cells present in spleens of TCRGagxAlb:Gag mice expressing
TCR chains other than the Tg Va3Vb12 (Figure 1B), or (3) anti-
CD3 is triggering tolerized cells expressing Tg Va3Vb12 chains
but is acting on endogenous non-Tg receptors also expressed
by tolerant CD8+ T cells (i.e., dual TCR). To address these possi-
bilities, we bred TCRGag and TCRGagxAlb:Gag mice onto aRag1/
background (Figure 1B), preventing expression of endogenous
non-Tg TCR chains, which require gene rearrangement.
Rag1/ TCRGag and TCRGagxAlb:Gag T cells responded similarlyto Rag1+/+ counterparts after stimulation with Gag peptide (Fig-
ure 1C), but Rag1/ tolerant TCRGagxAlb:Gag-CD8+ T cells failed
to proliferate to anti-CD3 (Figure 1C). Thus, proliferation of toler-
antRag1+/+ TCRGagxAlb:Gag T cells induced by anti-CD3 could not
reflect triggering of the tolerized TCR by a more potent stimulus.
To more directly determine whether anti-CD3 stimulation was
activating tolerant T cells via a second endogenously encoded
nontolerized receptor, we assessed CD69 expression after a 5 hr
in vitro stimulation, a time point when cells could still be gated
for expression of both Va3 and Vb12. Both Rag1+/+ and Rag1/
naive TCRGag T cells upregulated CD69 after stimulation with
anti-CD3 (Figure 1D, top panels). TolerantRag1+/+TCRGagxAlb:Gag
T cells upregulated CD69 with anti-CD3 similarly to naive
TCRGag T cells (Figure 1D, lower left panel), but tolerant Rag1/
TCRGagxAlb:Gag T cells failed to respond to anti-CD3 (Figure 1D,
lower right). Thus, on the Rag1+/+ background, a large fraction
of tolerant self-reactive CD8+ T cells express additional endoge-
nous TCR chains capable of transducing activation signals not
delivered after ligation of the tolerogen-specific receptor, sug-
gesting that TCR complexes that have not engaged a tolerogen
may remain functional in a tolerized cell.
Analysis of Tolerance in CD8+ T Cells Expressing
Defined Dual TCRs
These results raised fundamental questions of how the nonre-
sponsive phenotype is being maintained in a tolerized T cell
and how previously tolerized self-reactive T cells that happen
to express a second TCR might behave if a natural ligand for
the second TCR is encountered in the periphery. For further ex-
amination of these issues, it was necessary to develop a dual-
TCR murine model in which both expressed TCRs had known
specificities. Therefore, TCRGag and TCRGagxAlb:Gag mice were
crossed with P14 mice, which bear a TCR specific for the Db-
restricted Gp33 epitope of lymphocytic choriomeningitis virus
(LCMV). The resulting transgenic progeny again appeared
healthy, with no evidence of liver pathology, and contained
similar total splenocyte numbers to the parental mice. P14-
TCRGagxAlb:Gag mice had somewhat fewer total spleen CD8+ cells
at 10.6 ± 1.93 106 (± standard deviation for three mice per group)
compared to P14-TCRGag mice at 17.4 ± 2.33 106, likely the re-
sult of central and peripheral deletion of self-reactive CD8+ T
cells, as previously observed in single-receptor TCRGagxAlb:Gag
mice (Ohlen et al., 2002). In mice in which both TCRs were naive
(P14-TCRGag), 95% of CD8+ splenocytes expressed the
Va3Vb12 chains of the TCRGag receptor (Figure 2A) and 79%
expressed the Va2Vb8 chains of the P14 receptor (Figure 2B).
The Gag epitope with three cysteines is highly hydrophobic, and
it has not proven possible to produce a tetramer stable in solu-
tion—therefore, coexpression of both TCRs was assessed by
staining for the two Va or Vb chains. Seventy-two percent of cells
coexpressed Va2 and Va3 (Figure 2C), and more than 80% coex-
pressed Vb8 and Vb12 (data not shown), demonstrating that
the majority of cells have both specificities. These cells were
CD44low, similar to naive single-receptor TCRGag and P14 T cells
(Figure2D).Asdescribed insingle-receptor tolerant TCRGagxAlb:Gag
mice (Ohlen et al., 2002), P14-TCRGagxAlb:Gag mice also exhibited
a decreased frequency (21%) of Va3+Vb12+ Gag-specific CD8+
T cells compared toP14-TCRGag not expressing Gag as a self-pro-
tein (Figure 2A), attributable topartial deletion of these self-reactiveImmunity 28, 662–674, May 2008 ª2008 Elsevier Inc. 663
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Regulation of T Cell Tolerance at the TCR ComplexFigure 1. Activation of Tolerant CD8+ T Cells with Anti-CD3
(A) CFSE dilution in CD8-gated naive and tolerant splenocytes from TCRGag and TCRGagxAlb:Gag mice stimulated with an irrelevant Env (gray) or the Gag peptide,
anti-CD3, or antibody, to Va3 and Vb12 (black line) for 3 days in vitro.
(B) Splenocytes fromRag1+/+ andRag1/ TCRGag and TCRGagxAlb:Gag mice were analyzed for TCR expression by flow cytometry. Dot plots represent CD8-gated
cells, and the percentage of Va3+Vb12+ T cells within the CD8+ population is indicated (data representative of more than ten mice from each genotype).
(C) CFSE dilution in CD8-gated Rag1/ TCRGag and TCRGagxAlb:Gag splenocytes stimulated with Env (gray), Gag, or anti-CD3 (black line) for 3 days in vitro.
(D) Staining with anti-CD69 (black line) or isotype control antibody (gray),was analyzed on CD4-depleted Va3+Vb12+Rag1+/+ orRag1/TCRGag and TCRGagxAlb:Gag
splenocytes 5 hr after stimulation with anti-CD3. The mean fluorescence intensity (MFI) for each peak is provided, and data are representative of four separate
experiments.cells in the thymus and/or periphery (Morimoto et al., 2007; Ohlen
et al., 2002). In contrast, peripheral expression of Gag had no
marked impact on the percentage of cells expressing the
Va2Vb8 chains of the P14 receptor (Figure 2B). The decreased fre-
quency of Va3+Vb12+ T cells resulted in reduced (15%) dual-TCR T
cells expressing high amounts of bothVa2 and Va3 (Figure2C), but
these cells were uniformly identifiable as a CD44hi population (Fig-
ure 2D), consistent with previous antigen encounter through the664 Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc.Gag-specific TCR (Ohlen et al., 2002). P14-TCRGagxAlb:Gag mice
also possessed a population (73%) of apparently ‘‘single-recep-
tor’’ Va2+ T cells lacking high amounts of Va3 (Figure 2C). Such
cells were uniformly in the CD44lo compartment and expressed
high levels of Va2 Vb8 (P14) chains and very low Va3 Vb12 (Fig-
ure S1 available online), suggesting that their naive phenotype
resulted from failure to express sufficient Gag-reactive TCR to re-
spond to the self-protein. The frequency (15%) of Va2+Va3+CD44hi
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further analysis of the tolerant population. Sorting of cells on the
basis of CD44 and CD8 expression yielded highlypure populations
of naive and tolerant T cells (Figure S1). Thus, to avoid activation
and receptor downmodulation with antibodies specific for Va
and Vb chains during purification, we sorted tolerant cells from
P14-TCRGagxAlb:Gag mice in subsequent analysis on the basis of
the CD8+CD44hi phenotype.
Figure 2. Phenotype of Single- and Dual-
TCR CD8+ T Cells
(A–C)Splenocytes fromTCRGag,P14andtheF1naive
(P14-TCRGag) and tolerant (P14-TCRGagxAlb:Gag)
dual-TCR progeny were gated on CD8+ cells
and analyzed for expression of Va3 and Vb12
(TCRGag) (A), Va2 and Vb8 (P14) (B), or both sets
of TCRa chains (Va2 and Va3) (C). The percent
of double-positive CD8+ cells is inset.
(D) Single- and dual-receptor CD8+ T cells (circled
in [C]) were analyzed for CD44 expression. Inset
numbers represent MFI, and data are representa-
tive of more than ten mice from each genotype.
(E) Transgenic P14-TCRGag and P14-TCRGagxAlb:Gag
splenocytes (Thy1.2) were FACSsorted on the basis
of CD44 and CD8 expression (within rectangle
regions). Sorted T cells were combined 1:10
with congenic APC from a Thy1.1+ mouse, labeled
with CFSE, and stimulated with control, Gag,
or Gp33 peptide for 96 hr in vitro before CFSE dilu-
tion in Thy1.2+ T cells was assessed. The percent
of Thy1.2+ cells that had diluted CFSE is indicated.
Data are representative of three experiments.
Activation of Tolerant Dual-TCR T
Cells
So that the function of each of these
known TCRs could be investigated, pro-
liferation of purified dual-TCR T cells
was assessed in response to specific an-
tigen. Naive CD44loCD8+ P14-TCRGag
T cells and tolerant CD44hiCD8+
P14-TCRGagxAlb:Gag T cells were purified
by fluorescence-activated cell sorting
(FACS), mixed at 1:10 with congenic
splenocyte antigen-presenting cells (APC),
labeled with 5-(and-6-)-carboxyfluores-
cein diacetate succinimidyl ester (CFSE),
and stimulated with saturating antigen
concentrations (1 mg/ml) of either control,
Gag, or Gp33 peptide. Naive P14-TCRGag
T cells exhibited similar proliferative
responses to Gag and Gp33, with 89%
and 84% of cells respectively diluting
CFSE, suggesting relatively equivalent
signaling from both receptors at this anti-
gen dose (Figure 2E). Although tolerant
dual-receptor P14-TCRGagxAlb:Gag T cells
failed to appreciably dilute CFSE in re-
sponse to Gag, suggesting a uniformly
tolerant phenotype in this sorted popula-
tion, robust proliferation (86%) was observed after stimulation
with Gp33 (Figure 2E). Thus, the inability of a cell to respond
through a tolerized TCR did not preclude activation through
a second expressed receptor, suggesting that tolerance is being
regulated at the site of the assembled TCR complex.
Although tolerant P14-TCRGagxAlb:Gag T cells expressed the
Va3 and Vb12 chains required for Gag recognition, mismatched
TCR-chain pairing could reduce expression of Gag-reactive TCRImmunity 28, 662–674, May 2008 ª2008 Elsevier Inc. 665
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Therefore, relative expression of the Gag-specific TCR in naive
and tolerant dual-TCR cells was determined by assessment of
TCR downmodulation after peptide stimulation, an approach
previously demonstrated to induce abTCR-chain endocytosis
in an antigen-specific manner (Gladow et al., 2004; Valitutti
et al., 1995). Naive P14-TCRGag and tolerant P14-TCRGagxAlb:Gag
T cells downmodulated Va3 and Vb12 chains similarly after stim-
ulation with Gag (Figure S2), suggesting that equivalent amounts
of Vb12 were appropriately paired with Va3 on both cell types.
Downmodulation of Gag-reactive TCR chains was specific be-
cause Va2 and Vb8 (P14 receptor) expression was unchanged
after Gag stimulation (Figure S2) but was downmodulated after
Gp33 stimulation (data not shown). Thus, the tolerant phenotype
does not result from lack of appropriately paired TCR chains
capable of recognizing Gag.
Tolerant TCR Complexes Selectively Exhibit Proximal
Signaling Defects
We previously demonstrated that tolerant CD8+ T cells fail to ag-
gregate lipid rafts and form an immunologic synapse upon en-
counter with APC (Teague et al., 2006). To determine whether
this reflected an acquired global cellular defect or a property of
the tolerized TCR complex, we investigated lipid-raft accumula-
tion in dual-TCR cells at the point of T cell:APC contact. FACS-
sorted naive CD8+CD44lo and tolerant CD8+CD44hi dual-TCR
T cells were incubated with peptide-pulsed E10 tumor cells
as APCs, stained with labeled Cholera Toxin B-subunit (CTxB),
which specifically binds the raft marker monosialoganglioside
GM1 (Janes et al., 1999; Janes et al., 2000; Rouquette-Jazdanian
et al., 2005), and lipid-raft aggregation was visualized by confo-
cal microscopy of T cell:APC conjugates (Figure 3A). Images of
40 conjugates from each group (240 total images) were graded
for CTxB staining on a 0–5 scale, with 5 being most intense, and
each set of 40 scores was averaged (Figure 3B). Naive P14-
TCRGag CD8+ T cells efficiently aggregated rafts upon encounter-
ing either Gag+ or Gp33+ APCs, but not APCs pulsed with irrele-
vant Env peptide (Figure 3A). Tolerant P14-TCRGagxAlb:Gag T cells
failed to aggregate lipid rafts with Gag+ APCs but did with Gp33+
APCs (Figure 3A). Thus, the tolerant TCR seems selectively
unable to mobilize synapse formation.
Because antigen-specific TCR complexes appear to function
independently in dual-TCR T cells, signals transduced from
competent and tolerant TCR should be discernable. We previ-
ously demonstrated tolerant CD8+ T cells are defective in phos-
phorylation of ERK and JNK kinases after antigen stimulation
(Ohlen et al., 2002). To determine whether these signaling
defects reflect events intimate to only tolerized TCR complexes
or a more global compromise of downstream signaling compo-
nents, we stimulated purified naive and tolerant T cells with
Gag or Gp33 (Figures 3C and 3D; solid lines) or an irrelevant
control peptide (gray filled) presented by APCs from Thy1.1
congenic mice and assessed responses in Thy1.2-gated cells.
As a control for maximal detectable responses, cells were stim-
ulated with anti-CD3, which phosphorylated ERK and JNK by 30
min in both T cell subsets. Naive P14-TCRGag T cells phosphor-
ylated ERK and JNK in response to both Gag and Gp33-antigen
(Figure 3C). In contrast, tolerant P14-TCRGagxAlb:Gag T cells failed
to phosphorylate either ERK or JNK in response to Gag but did666 Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc.after Gp33 stimulation (Figure 3D, and pooled data from three
separate experiments in Figure S3).
So that it could be determined whether this phenomenon of
TCR-specific tolerance in dual-TCR cells was unique to the
Gag-reactive TCR, naive P14-TCRGag mice were alternatively
tolerized in vivo through the P14 receptor by repeated injection
of high doses of Gp33 peptide in incomplete Freund’s adjuvant
(IFA) as previously described (Aichele et al., 1995). FACS-sorted
CD8+CD44hi T cells from IFA-Gp33-treated mice responded nor-
mally to Gag but exhibited blunted responsiveness to Gp33
(63% failed to dilute CFSE), suggesting that the majority of cells
under these tolerizing conditions had alternatively selectively
tolerized the Gp33-specific TCR (Figure S4).
Rescue of Tolerant TCR Antigen Responsiveness
Tolerant CD8+ T cells have been rescued from the tolerant state
in vitro by the induction of proliferation with high doses of cyto-
kines (Teague et al., 2006). To determine whether similar rescue
might occur in vivo in dual-TCR T cells if the competent nontoler-
ant TCR encountered its antigen, we examined the effect of in
vivo LCMV infection. B6 or Alb:Gag mice received 13 105 sorted
naive or tolerant dual-TCR T cells, respectively, and recipients
subsequently infected with LCMV. Seven days after infection,
similar extensive expansion of naive and tolerant Va2+Va3+
dual-receptor CD8+ T cells was detected in the blood of respec-
tive hosts (Figure 4A), as well as in the spleens (23.1% of 59.8 ±
0.93 106 and 21.4% of 57.4 ± 4.73 106 total CD8+ cells, respec-
tively, with three mice/group). Proliferation required stimulation
through the P14 receptor because alternative immunization
with Gag-peptide-pulsed E10 cells failed to induce expansion
of transferred tolerant dual-TCR T cells (Figure 4B), although
these cells expanded to E10 cells pulsed with Gp33 peptide,
similar to the proliferative response of naive T cells immunized
with either Gag or Gp33 peptide. The absence of Gag respon-
siveness from sorted tolerant dual-TCR T cells confirmed that
the infused cells were uniformly tolerant, and the observed ex-
pansion to Gp33 was not the result of activation of a contaminat-
ing population of nontolerant cells.
To determine whether the induced in vivo proliferation of toler-
ant dual-receptor T cells rescued function, we analyzed antigen
responsiveness ex vivo after 7 day LCMV infection. Because
most responding cells at this time point are entering a pro-
grammed contraction phase and poised to undergo apoptosis
(Blattman et al., 2003; Grayson et al., 2002), analysis of prolifera-
tive responses ex vivo was not feasible. Therefore, dual-TCR
T cells were analyzed for early signaling events that distinguish
a tolerant TCR, namely ERK and JNK phosphorylation 30 min af-
ter ex vivo stimulation. B6-Thy1.1 or Alb:GagThy1.1 mice received
13105 sorted naive or tolerant dual-TCR T cells (Thy1.2), respec-
tively. Recipients were infected with LCMV, and Thy1.2+CD8+
T cells were examined ex vivo 7 days later. In contrast to tolerant
P14-TCRGagxAlb:Gag T cells from noninfected mice (Figure 3D), ex-
panded P14-TCRGagxAlb:Gag T cells phosphorylated ERK and JNK
after stimulation with either Gag or Gp33, similar to transferred
nontolerant P14-TCRGag T cells (Figure 4C and Figure S3).
Such rescued cells expressed similar amounts of surface Va3
and Vb12 as did naive and tolerant dual-TCR cells analyzed
from noninfected mice (Figure 4D). Thus, restoration of Gag
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(A and B) P14-TCRGag and P14-TCRGagxAlb:Gag splenocytes were sorted on the basis of CD44 and CD8 expression. CD8+ T cells (blue) were stained for CTxB
(yellow to white) after 30 min encounter with peptide-pulsed APCs (green) and visualized by confocal microscopy (A) and graded 0-5 for CTxB staining intensity
(B). Average scores from three experiments with P14-TCRGag (open bars) and P14-TCRGagxAlb:Gag (filled bars) cells are presented with standard error of the mean.
(C and D) Sorted naive P14-TCRGag (C)and tolerant P14-TCRGagxAlb:Gag (D) T cells (Thy1.2) were combined 1:10 with APCs from a congenic Thy1.1+ mouse and
stimulated with control (gray filled), Gag or Gp33 peptide (black lines), or anti-CD3 (black lines) in vitro. Phosphorylation of ERK and JNK in cells gated for Thy1.2
and CD8 expression (left) was assessed after 30 min by intracellular staining with phospho-specific antibodies. MFI values for each peak are inset, and data are
representative of four separate experiments.Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc. 667
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cific TCR expression.
To examine whether such restoration of signaling detected
in vitro in previously tolerant cells also improved T cell function
in vivo, we again transferred 1 3 105 sorted naive or tolerant
dual-TCR T cells into B6 or Alb:Gag mice, respectively. Recipi-
ents were infected with LCMV and challenged with 1 3 106 live
Gag+ FBL tumor cells at 7, 14, or 21 days after infection, repre-
senting the peak, contraction, and stable memory phases of
T cell activation, respectively (Antia et al., 2005) (Figure 5A).
At day 7, both naive and tolerant dual-TCR T cell populations
had similarly expanded, and all recipients (10/10 per group) re-
sisted tumor challenge, surviving beyond 40 days of observation
(Figure 5B), whereas control mice, which either did not receive
T cells or received T cells but were not infected, developed fatal
tumors by day 15 (Figure 5B and data not shown). Lytic activity of
expanded naive and tolerant dual-TCR T cells was specific and
nearly equivalent because LCMV-infected mice that had re-
ceived 1 3 105 sorted naive or tolerant cells specifically elimi-
nated CFSE-labeled target cells pulsed with Gag peptide infused
on day 7 (Figure S5). No autoimmune liver disease was detected
in mice after infection and expansion of Gag-reactive T cells
(data not shown), consistent with the resistance of hepatic cells
to T cell-mediated damage previously observed in this model
(Morimoto et al., 2007; Ohlen et al., 2002; Teague et al., 2006).
At 14 days after infection, both naive and tolerant dual-TCR T
cell populations had contracted comparably (Figure 5A). How-
ever, Alb:Gag recipients of tolerant P14-TCRGagxAlb:Gag T cells
were less resistant to tumor challenge (2/10 survived long-
term) than either B6 recipients of naive P14-TCRGag T cells (10/10)
(Figure 5C) or Alb:Gag recipients that had been challenged
on day 7 (10/10) (Figure 5B). Nonetheless, Alb:Gag recipients
challenged on day 14 still demonstrated prolonged median sur-
vival (25 days) and 20% long-term survival, compared to control
mice receiving no T cells with a median survival of 12 days and
death from progressive tumor by day 16 (Figure 5C). The antitu-
mor activity observed at day 7 and 14 after LCMV cannot be
explained simply by expanded cell numbers because with the
dramatic contraction of spleen size evidenced by day 14 after in-
fection, as previously reported (Cheng and Greenberg, 2002;
Lohman et al., 1996), the total number of dual-TCR T cells had
declined to numbers smaller than those detected in unimmu-
nized P14-TCRGagxAlb:Gag mice (Figure 2), which had no ability
to resist viable FBL tumor challenge (data not shown).
The frequency of Va2+Va3+ T cells at day 21 was modestly
higher (approximately 2-fold) in recipients of naive dual-TCR
T cells compared to recipients of tolerant cells, but both T cell
populations remained detectable at stable amounts out to at
least day 40 (Figure 5A). After challenge with FBL on day 21 post-infection, eight out of ten recipients of naive P14-TCRGag T cells
were protected (Figure 5D). In contrast, survival in recipients of
tolerant P14-TCRGagxAlb:Gag T cells was similar to that in mice re-
ceiving no T cells (Figure 5D). These data suggest the activation
and proliferation of tolerant dual-TCR T cells induced through the
LCMV-specific TCR only transiently restored responsiveness to
Gag, with the tolerant phenotype ultimately reacquired.
To determine whether the apparent reacquisition of tolerance
represented an intrinsic cellular defect or a consequence of the
tolerizing Alb:Gag environment, we transferred 1 3 105 FACS-
sorted tolerant P14-TCRGagxAlb:Gag T cells into normal B6 hosts
(lacking peripheral Gag antigen), which were then infected with
LCMV and later challenged with FBL. Analysis at 7 and
21 days after infection revealed that Va2+Va3+ dual-TCR T cells
had expanded and then contracted (Figure 6A). On day 21 after
LCMV infection, mice were challenged with FBL tumor as previ-
ously described, and survival was assessed. Control mice re-
ceiving no T cells died of progressive tumor by day 18, but all
recipients of tolerant dual-TCR T cells survived (Figure 6B). Thus,
the reduced anti-FBL activity of tolerant P14-TCRGagxAlb:Gag
T cells observed in Alb:Gag hosts at day 14 and complete
absence by day 21 after infection (Figures 5C and 5D) likely
reflected reacquisition of tolerance because of recurrent
encounter with tolerogen in the periphery.
Repeated T Cell Rescue after Reacquisition
of Tolerance
The observation that tolerant CD8+ T cells recognizing a self-
tumor antigen can be activated and expanded via a second
TCR to mediate antitumor activity, even transiently, suggests
that the employment of dual-TCR T cells in adoptive therapy in
which a tumor-reactive TCR has been intentionally introduced
into a cell with known specificity might have therapeutic poten-
tial. So that it could be determined whether periodical restimula-
tion of such cells in a tolerizing environment by immunization
through the nontolerized TCR might provide a means to sustain
donor T cell efficacy, Alb:Gag host mice received 13 105 FACS-
sorted tolerant P14-TCRGagxAlb:Gag T cells, primary infection with
LCMV followed. At day 30, after these cells had demonstrated
reacquisition of the tolerant phenotype and no longer protected
against tumor challenge (Figure 5D), mice were boosted by injec-
tion of either Gag- or Gp33-peptide-pulsed B6 splenocytes.
Analysis of peripheral blood lymphocytes (PBLs) 7 days later re-
vealed marked expansion of Va2+Va3+ dual-TCR CD8+ T cells if
boosted with APCs presenting Gp33 but not Gag (Figure 7A). If
challenged with FBL tumor at day 7 after boosting, 8 out of 12
mice immunized with Gp33 survived beyond 40 days, whereas
mice immunized with Gag had a median survival of 15 days
and all died from progressive tumor (Figure 7B). The cells thatFigure 4. In Vivo Expansion and Rescue of Tolerant Dual-TCR T Cells
(A and B) Transgenic naive P14-TCRGag and tolerant P14-TCRGagxAlb:Gag splenocytes were FACS sorted on the basis of CD44 and CD8 expression, and 13 105
sorted T cells were transferred into B6 or Alb:Gag recipients. Recipient mice were immunized with either LCMV (A) or peptide-pulsed irradiated E10 cells (B). Inset
numbers are percent of total CD8+ cells from PBLs at day 7 after immunization.
(C) Thy1.1 or Alb:GagThy1.1 mice received 13 105 FACS-sorted naive P14-TCRGag or tolerant P14-TCRGagxAlb:Gag T cells, and recipients were infected with LCMV
for 7 days. Recipient splenocytes were stimulated ex vivo with control Env (gray filled), Gag or Gp33 peptide, or anti-CD3 (black lines), and phosphorylation of ERK
and JNK in cells gated for CD8 and Thy.1.2 expression (circled in dot plots on the left) was assessed after 30 min. The MFI for each peak is inset.
(D) Dual-TCR T cells were analyzed for relative TCR expression directly ex vivo from noninfected mice or after CD8 and CD44 FACS sorting and transfer into B6 or
Alb:Gag recipients and infection with LCMV for 7 days. Splenocytes were CD4 depleted, and expression of Va3 and Vb12 was assessed on cells gated for Va2
expression by flow cytometry. Data are representative of three separate experiments.Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc. 669
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TCR T Cells
B6 or Alb:Gag mice received 13 105 sorted naive P14-TCRGag or tolerant P14-
TCRGagxAlb:Gag T cells, respectively, and recipients were infected with LCMV.
At 7, 14, 21, and 40 days after infection, recipient PBLs were analyzed for
Va2+Va3+CD8+ T cells (A). Error bars are standard deviation of 20 mice per
group from four separate experiments. Recipients were challenged with live
FBL tumor 7 days (B), 14 days (C), and 21 days (D) after LCMV infection.670 Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc.provided protection after proliferation induced by boosting with
Gp33 expressed similar amounts of the Va3 TCR chain from
the Gag-specific TCR as did cells remaining nonresponsive after
boosting with Gag (Figure 7A), suggesting functional recovery re-
flected qualitative not quantitative alterations in the Gag-specific
TCR complex.
The results of these and the previous experiments suggest
that the tolerant TCR complex in dual-TCR T cells must be mo-
lecularly or biochemically distinct from the functional complex.
Initial efforts to dissect this have revealed that the tolerant com-
plex is structurally less stable than functional complexes, as
evidenced by a markedly reduced ability to coprecipitate CD33
and CD3z with the tolerant Vb12-containing complexes com-
pared to the Vb8 complexes (Figure S6). This did not reflect pro-
portionally reduced surface expression of CD33 or total cellular
CD3z, as clearly demonstrated by the study of tolerant Rag1/
single-TCR T cells expressing only the tolerant TCR complex.
This selective instability of tolerant TCR complexes likely con-
tributes to the dysfunction and inability to mobilize synapse
Survival was monitored for 40 days after tumor challenge, and each graph
represents pooled data from the indicated number of mice (n) per group
from two separate experiments.
Figure 6. In Vivo Expansion and Anti-FBL Effector Function in the
Absence of Tolerizing Peripheral Antigen
(A) The frequency of Va2+Va3+CD8+ cells in PBLs from B6 recipients of 13 105
FACS-sorted CD44hi CD8+ tolerant P14-TCRGagxAlb:Gag T cells was assessed
at days 7 and 21 after LCMV infection (or no infection control recipients).
(B) B6 mice receiving 13 105 sorted tolerant P14-TCRGagxAlb:Gag T cells (black
line) or no T cell controls (bold gray line) were challenged with 13 106 live FBL
tumor by i.p injection 21 days after LCMV infection. Survival was monitored for
40 days, and the graph represents pooled data from the indicated number of
mice (n) per experimental group from two independent experiments.
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terize, and compare the components of the tolerant complex.
DISCUSSION
The generation of an effective CD8+ T cell response generally
requires that specific CD8+ T cells expand after recognition
of antigen—a capacity usually lost by tolerant T cells (Ohlen
et al., 2002; Teague et al., 2006). However, how this nonrespon-
sive phenotype is maintained in tolerized T cells for subsequent
encounters with cognate antigen remains unclear. Our initial
analysis of tolerant self-reactive CD8+ T cells suggested that
concurrently expressed endogenous TCRs that are not engaged
might remain functional in such tolerant cells, and our subse-
quent studies with dual-TCR T cells expressing two known dis-
tinct TCR complexes demonstrated that tolerant dual-TCR
T cells can be induced to proliferate by triggering of a competent
Figure 7. Restimulation of Contracted and Tolerant Dual-TCR
T Cells within the Tolerizing Environment
(A) Va2+Va3+CD8+ cells from Alb:Gag recipients of 1 3 105 FACS-sorted
CD44hi CD8+ tolerant P14-TCRGagxAlb:Gag T cells were assessed 30 days after
LCMV infection and 7 days after secondary boost immunization (day 37) with
either Gag or Gp33 peptide-pulsed B6 splenocytes.
(B) At day 37 (7 days after boost), mice were challenged with live FBL tumor
and survival monitored for 40 days. The graph represents pooled data from
the indicated number of mice (n) per experimental group from three indepen-
dent experiments.TCR signaling cascade accessible to the nonself-reactive recep-
tor. Such signaling was not observed after engagement of the
tolerized TCR, which displayed defective phosphorylation of
downstream molecules and an inability to mobilize lipid rafts to
form a synapse. Compromised proximal and distal TCR signal-
ing events have previously been assigned a role in maintenance
of T cell tolerance (Chiodetti et al., 2006; Murtaza et al., 2001;
Ohlen et al., 2002; Tanchot et al., 1998), particularly in CD4+
T cells tolerized to endogenous peripherally expressed proteins
with signaling deficiencies such as ERK phosphorylation impli-
cated in tuning the activation threshold, but the defects have
generally been perceived to reflect global cellular changes
(Grossman and Paul, 1992; Singh and Schwartz, 2003). Such
adaptive tolerance to endogenous proteins bears similarities to
our model. However, in the tolerance induced in vivo by encoun-
ter with a class I-restricted self-protein, CD8+ T cells can coex-
press autonomously functioning nontolerant class I-restricted
TCR complexes, suggesting that such adaptive tolerance may
not be cell intrinsic but regulated at the TCR. This in vivo toler-
ance differs from inferences provided by the study of in vitro
tolerogenic signals delivered by antagonist peptides, which
demonstrated TCR trans-inhibition in dual TCR cells (Dittel
et al., 1999; Robertson and Evavold, 1999; Yang and Grey,
2003). This disparity likely reflects fundamental differences in
how tolerance has been induced or perhaps more importantly
maintained long term in a viable tolerized cell.
Consistent with tolerance being regulated by control of proxi-
mal signaling events initiated at the tolerized TCR complex, stim-
ulation of the TCR specific for a foreign protein resulted in a nor-
mal signaling cascade and proliferative response. This result
implies that the assembled complexes of tolerant and functional
TCRs must differ, presumably as a result of selective modifica-
tions of TCR-complex components and/or by the addition of
inhibitory or removal of activating molecules. Analysis of tolerant
TCR complexes indeed demonstrated that the integrity of these
complexes was compromised, as reflected by impaired associ-
ation of the critical signaling components, CD33 and CD3z, with
the TCR chains. Instability of tolerant TCR complexes has previ-
ously been observed in an alternative in vivo model of CD8+ T cell
tolerance to a self-antigen (Guillaume et al., 2003), and our re-
sults suggest that instability can specifically and selectively tar-
get the TCR complexes that have been engaged by the tolero-
gen. Impaired interactions of TCR-complex molecules with
each other could impact the ability to crossphosphorylate mole-
cules, propagate signals, and engage cytoskeletal elements
to form a synapse (Gil et al., 2002) but will also confound efforts
to definitively characterize the molecules associated with the
complex.
Rescue of function of the tolerant TCR by signaling through the
functional TCR likely is a consequence of proliferation because
we and others have previously demonstrated that inducing
proliferation of anergic T cells via stimulation with pharmacologic
doses of cytokines can also restore antigen responsiveness
(DeSilva et al., 1991; Teague et al., 2006). Thus, the modifications
of tolerant TCR complexes responsible for maintaining the non-
responsive phenotype are presumably reset during proliferation
in which large numbers of new TCR complexes lacking the
induced inhibitory changes are assembled and expressed, en-
abling competent TCR signaling and function upon subsequentImmunity 28, 662–674, May 2008 ª2008 Elsevier Inc. 671
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in the absence of further tolerizing signals, consistent with stud-
ies demonstrating that function can be rescued by removal from
the tolerizing environment (Ohlen et al., 2002; Ramsdell and
Fowlkes, 1992; Rocha et al., 1993), but the observed reacquisi-
tion of tolerance in cells remaining in the tolerizing environment
suggests tolerance in vivo is actively maintained by repeated
encounters with the tolerogen. Although some studies have
suggested reacquisition of tolerance may lead to a more pro-
nounced state of nonresponsiveness (Tanchot et al., 2001),
which could conceivably limit the number of times tolerant T cells
can be effectively rescued, our data suggest cells can clearly be
rescued more than once.
Our observation that T cell tolerance is regulated at the level of
self-reactive TCR complexes not only provides insights into the
mechanisms regulating T cell tolerance but also has therapeutic
implications, because the transfer of genes encoding tumor an-
tigen-specific abTCR into normal T cells expressing endogenous
receptors is now being pursued as a strategy to generate tumor-
reactive T cells for adoptive immunotherapy (Gladow et al., 2004;
Heemskerk et al., 2004; Hughes et al., 2005; Morgan et al., 2006;
Roszkowski et al., 2005; Stanislawski et al., 2001). Infusion of T
cells expressing TCR capable of recognizing tumor antigens
and mediating antitumor effector function does not always trans-
late into beneficial clinical responses, and one potential obstacle
is that in vivo encounter with candidate tumor antigens, which
are mostly self-proteins, might be tolerogenic. Moreover, factors
present in the tumor microenvironment may tolerized or anergize
reactive T cells after infusion into patients (Gabrilovich, 2004;
Kusmartsev et al., 2005; Pardoll, 2003). In vitro experiments
have suggested that expressing a TCR specific for a tumor-
associated antigen in a T cell expressing an endogenous TCR
specific for a known foreign antigen such as a virus might provide
a means to more efficiently expand antitumor responses (Heem-
skerk et al., 2004). Our data suggest extending this approach
to periodically deliver appropriate activation signals to dual-
TCR cells via a TCR not reactive with a tumor antigen might
also rescue infused T cells that have become nonresponsive
in vivo.
EXPERIMENTAL PROCEDURES
Mice
Alb:Gag, TCRGag (naive) and TCRGagxAlb:Gag (tolerant) mice have previously
been described (Ohlen et al., 2002; Ohlen et al., 2001). C57BL/6 (B6),
Thy1.1, and B6-Rag1/ mice were purchased from Jackson Labs. P14
mice were a gift from K. Murali-Krishna (University of Washington), and dual-
TCR mice were generated by crossing of TCRGag and TCRAlb:Gag mice with
P14. Mice were maintained under specific pathogen-free conditions. All animal
protocols were approved by the University of Washington Department of
Comparative Medicine’s Animal Care Committee.
Cell Lines, Antibodies, and Reagents
FBL and E10 tumor cell lines have previously been described (Ohlen et al.,
2002; Teague et al., 2006). FBL-Gag peptide (CCLCLTVFL), FBL-Env peptide
(EPLTSLTPRCNTAWNRLKL), and LCMV-Gp33-peptide (KAVYNFATM) were
purchased from Global Peptide. CD4 depletion was performed with Dynal
magnetic beads. Antibodies (Abs) to cell-surface molecules were from BD
PharMingen. Phospho-specific monoclonal antibodies (mAbs) were from
Cell Signaling. Cholera toxin subunit-B conjugate and 5-(and-6-)-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) were from Molecular Probes.672 Immunity 28, 662–674, May 2008 ª2008 Elsevier Inc.FACS Sorting
So that activation of T cells during FACS sorting by Ab specific for Va/Vb TCR
chains could be avoided, naive P14-TCRGag T cells were isolated on the basis
of CD8 and CD44low expression, whereas tolerant P14-TCRGagxAlb:Gag T cells
were sorted on the basis of CD8 and CD44hi expression.
T Cell Stimulation
In vitro proliferation was assessed by labeling of cells with 1 mg/ml CFSE for
30 min at 37C and stimulation of 53 106 cells/ml with 1 mg/ml soluble peptide
or Ab. In vivo T cell expansion was analyzed after intravenous (i.v.) transfer of
1 3 105 sorted T cells into B6 or Alb:Gag recipient mice and either infection
with 23 105 PFU/ml LCMV or immunization with 53 106 peptide-pulsed irra-
diated APCs. T cells were boosted in vivo by administration of 53 106 peptide-
pulsed syngeneic splenocytes intraperitoneally (i.p.). Live tumor challenge was
performed by administration of 1 3 106 FBL cells i.p. Mice were monitored
daily and euthanized upon detection of tumor-induced ascites and are
described in the text as having died from progressive tumor, which uniformly
occurs within 24–48 hr of visible ascites.
Intracellular phosphorylation of ERK and JNK was assessed by stimulation
of cells directly ex vivo with 1 mg/ml soluble peptide or Ab for 30 min. Cells were
fixed and permeabilized in Cytofix/Cytoperm buffers (BD PharMingen) and
stained with anti-phospho-ERK or anti-phospho-JNK followed by secondary
anti-rabbit-PE.
In Vivo Induction of T Cell Tolerance with Peptide and IFA
Tolerance through the P14 TCR was induced by methods previously described
by others (Aichele et al., 1995). In brief, P14-TCRGag mice received three i.p.
injections of 500 mg Gp33 peptide emulsified 1:1 in incomplete Freund’s
adjuvant at 3 day intervals. Tolerance was assessed ex vivo 10 days after
the final injection.
Confocal Microscopy
Naive and tolerant CD8+ dual-TCR T cells were purified by FACS sorting and
stimulated for 30 min with peptide-pulsed E10 cells (CD4+) in a 2:1 ratio, and
synapse formation was assessed and scored by confocal microscopy as pre-
viously described (Teague et al., 2006).
SUPPLEMENTAL DATA
Six figures are available at http://www.immunity.com/cgi/content/full/28/5/
662/DC1/.
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